Form DEF 14A KRYSTAL BIOTECH For: 3 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Krystal Biotech Inc (KRYS)
Krystal Biotech Inc stock price live, this page displays NASDAQ KRYS stock exchange data. View the KRYS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Krystal Biotech Inc real time stock price chart below.
What Is the Krystal Biotech Inc Stock Price Today?
The Krystal Biotech Inc stock price today is 272.66.
What Is the Stock Symbol for Krystal Biotech Inc?
The stock symbol for Krystal Biotech Inc is "KRYS."
What Stock Exchange Does Krystal Biotech Inc Trade On?
Krystal Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Krystal Biotech Inc a Good Stock to Buy?
Determining whether Krystal Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KRYS quote. (ISIN: US5011471027)
What Is the Krystal Biotech Inc Stock Price Today?
The Krystal Biotech Inc stock price today is 272.66.
What Is the Stock Symbol for Krystal Biotech Inc?
The stock symbol for Krystal Biotech Inc is "KRYS."
What Stock Exchange Does Krystal Biotech Inc Trade On?
Krystal Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Krystal Biotech Inc a Good Stock to Buy?
Determining whether Krystal Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KRYS quote. (ISIN: US5011471027)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
271.62
277.47
52 wk Range
122.80
298.30
KRYS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
271.62277.47
52 wk Range
122.80298.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KRYS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
315.00
Upside
+15.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Krystal Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form DEF 14A KRYSTAL BIOTECH For: 3 April
- Investing.com
- Krystal Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech Inc Earnings Call Summary for Q4/2025
- Krystal Biotech exceeded Q4 2025 expectations with EPS of $1.70 (vs $1.58 forecast) and revenue of $107.1M (vs $106.16M forecast), driving a 4.54% pre-market stock surge to $289.
- The company reported strong financial metrics with 94% gross margin, Q4 net income of $51.4M, full-year net income of $204.8M, and cash/investments of $955.9M.
- Global expansion of flagship product VYJUVEK contributed to a 34% YTD revenue increase compared to 2024, with over 500 unique prescribers in the U.S. and significant international uptake.
- CEO Krish Krishnan highlighted operating profitability while expanding VYJUVEK access globally, with plans to extend distributor agreements to over 40 countries in 2026.
- Management forecasts ex-U.S. markets as the primary revenue growth driver for 2026, with 2026 non-GAAP R&D and SG&A expenses projected between $175M-$195M.
Last Updated: 2026-02-17, 09:38 a/m
Read Full TranscriptCompare KRYS to Peers and Sector
Metrics to compare | KRYS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKRYSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 39.2x | −1.9x | −0.5x | |
PEG Ratio | 0.31 | −0.09 | 0.00 | |
Price/Book | 6.6x | 2.6x | 2.6x | |
Price / LTM Sales | 20.6x | 100.2x | 3.2x | |
Upside (Analyst Target) | 11.9% | 206.2% | 44.7% | |
Fair Value Upside | Unlock | 30.7% | 5.7% | Unlock |
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 315.00
(+15.53% Upside)
Earnings
Latest Release
Feb 17, 2026
EPS / Forecast
1.70 / 1.58
Revenue / Forecast
107.1M / 106.16M
People Also Watch
FAQ
What Is the Krystal Biotech (KRYS) Stock Price Today?
The Krystal Biotech stock price today is 272.66 USD.
What Stock Exchange Does Krystal Biotech Trade On?
Krystal Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Krystal Biotech?
The stock symbol for Krystal Biotech is "KRYS."
What Is the Krystal Biotech Market Cap?
As of today, Krystal Biotech market cap is 8.01B USD.
What Is Krystal Biotech's Earnings Per Share (TTM)?
The Krystal Biotech EPS (TTM) is 6.84.
When Is the Next Krystal Biotech Earnings Date?
Krystal Biotech will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is KRYS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Krystal Biotech Stock Split?
Krystal Biotech has split 0 times.
How Many Employees Does Krystal Biotech Have?
Krystal Biotech has 295 employees.
What is the current trading status of Krystal Biotech (KRYS)?
As of Apr 21, 2026, Krystal Biotech (KRYS) is trading at a price of 272.66 USD, with a previous close of 276.50 USD. The stock has fluctuated within a day range of 271.62 USD to 277.47 USD, while its 52-week range spans from 122.80 USD to 298.30 USD.
What Is Krystal Biotech (KRYS) Price Target According to Analysts?
The average 12-month price target for Krystal Biotech is 315.00 USD, with a high estimate of 380 USD and a low estimate of 241 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +15.53% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.